NCT05479578View on ClinicalTrials.gov

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
Interventions
DRUG

Cyclophosphamide

Given PO

DRUG

Dexamethasone

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rashmi Verma, MD

OTHER